Efficacy of P2B001 in patients with Early Parkinson’s Disease

P2B001, an investigational oral therapy combining low doses of pramipexole and rasagiline, has been shown to safely and effectively reduce symptoms in people with early-stage Parkinson’s disease. Data from Phase 2b and Phase 3 clinical trials revealed that P2B001 performed as well as extended-release pramipexole (marketed as Mirapex ER), with fewer sleep-related side effects. The findings were presented at the Parkinson Study Group’s Annual Meeting in a poster by Dr. Henry Moore from the University of Miami. P2B001, a once-daily combination pill, requires no dose titration and demonstrated greater reductions in motor and daily living symptoms compared to a placebo. The trials highlighted that P2B001 is more effective than its components used separately and as effective as Mirapex ER, but with a better safety profile. Patients treated with P2B001 reported significantly fewer issues with daytime sleepiness and other side effects commonly associated with dopamine therapies. The treatment, designed to mimic and enhance dopamine effects in the brain, may serve as a valuable first-line option for early Parkinson’s disease patients, especially those managed by general neurologists and primary care physicians. Pharma Two B plans to advance P2B001 toward a new drug application to the U.S. Food and Drug Administration.